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Meta-analysis of genetic association with diagnosed Alzheimer's disease identifies novel
risk loci and implicates Abeta, Tau, immunity and lipid processing
Introduction (word count: 149 of 150 word limit)
Late-onset Alzheimer’s disease (LOAD, onset age > 60 years) is the most prevalent
dementia in the elderly1, and risk is partially driven by genetics2. Many of the loci
responsible for this genetic risk were identified by genome-wide association studies
(GWAS)3–8. To identify additional LOAD risk loci, we performed the largest GWAS to date
(92,255 individuals), analyzing both common and rare variants. We confirm 20 previous
LOAD risk loci and identify four new genome-wide loci (IQCK, ACE, ADAM10, and
ADAMTS1). Pathway analysis of these data implicates the immune system and lipid
metabolism, and for the first time tau binding proteins and APP metabolism. These
findings show that genetic variants affecting APP and Aβ processing are not only 
associated with early-onset autosomal dominant AD but also with LOAD. Analysis of AD
risk genes and pathways show enrichment for rare variants (P = 1.32 x 10-7) indicating that
additional rare variants remain to be identified.
Main Text (word count: 1,991)
Previous work identified 19 genome-wide significant signals in addition to APOE9, that influence
risk for LOAD. These account for ~31% of the genetic variance of LOAD2, leaving the majority of
genetic risk uncharacterized10. To search for additional signals, we conducted a GWAS meta-
analysis of non-Hispanic Whites (NHW) using a larger sample (17 new, 38 total datasets) from
four consortia (ADGC, CHARGE, EADI, and GERAD). This sample increases the previous
discovery sample (Stage 1) by 29% for cases and 13% for controls (N = 21,982 cases; 41,944
controls) (Supplementary Table 1, 2 and 3, and Supplementary Note). To sample both common
and rare variants (minor allele frequency MAF ≥ 0.01, and MAF < 0.01, respectively), we imputed 
the discovery datasets using a 1000 Genomes reference panel consisting of 36,648,992 single-
nucleotide variants, 1,380,736 insertions/deletions, and 13,805 structural variants. After quality
control, 9,456,086 common variants and 2,024,664 rare variants were selected for analysis (a
62.7% increase from the 2013 common variant analysis). Genotype dosages were analyzed
within each dataset, and then combined with meta-analysis (Supplementary Figures 1 and 2
and Supplementary Table 4). The Stage 1 discovery meta-analysis was first followed by
replication Stage 2 using the I-select chip we previously developed in Lambert et al (including
11,632 variants, n=19,884) and finally stage 3A (n=7,026). The final sample was 34,312 clinical
AD cases and 57,943 controls.
Meta-analysis of Stages 1 and 2 produced 21 associations with P ≤ 5 x 10-8 (Table 1 and
Figure 1). Of these, 18 were previously reported as genome-wide significant and three of them
are signals not initially described in Lambert et al: the rare R47H TREM2 coding variant previously
reported by others11–13; ECDH3 (rs7920721) which was recently identified as a potential genome-
wide significant AD risk locus in several studies23-25 and ACE (rs138190086). In addition, four
signal showed suggestive association with a P-value<5.10-7 (respectively rs593742, rs830500,
rsrs7295246 and rs138190086 for ADAM10, ADAMTS1, ADAMTS20, and IQCK).
Stage 3A replication and meta-analysis of all three stages for these 6 variants (excluding
the TREM2 signal, see Supplementary Figure 1 for workflow) identified five genome-wide
significant sites. In addition to ECDH3, this included four new genome-wide AD risk signals at
IQCK, ADAMTS1, ACE and ADAM10 not previously described in other AD GWAS (Table 2,
Supplementary Table X and Supplementary Figures 4-8). ACE and ADAM10 were previously
reported as AD candidate genes14–17 that were not replicated in some subsequent studies18–22.
We also extended the analyses of the two loci (NME8 and MEF2C) in stage 3 that were previously
genome-wide significant in our 2013 meta-analysis. These loci were not significant in our current
study and will deserve further investigations. Of note, GCTA-COJO26 conditional analysis of the
genome-wide loci indicates that TREM2 and three other loci (BIN1, ABCA7, and PTK2B/CLU)
have multiple independent LOAD association signals (Supplementary Table 6), suggesting that
the genetic variance associated with some GWAS loci is probably under-estimated.
We also selected 23 SNPs from stage 1 (18 common variants in loci not well captured in
the I-select chip, P<5x10-6 and 5 rare variants with MAF<0.01, P<10-5, see supplementary
material and methods section for full selection criteria) for replication in stage 3B (including
populations of stage 2 and stage 3A). We nominally replicated a relatively rare variant
(rs71618613) within an intergenic region on 5p13.3 (MAF = 0.01; P = 6.8x10-3; combined-P =
3.3x10-7)(Table 2 and supplementary Table X).
To evaluate the biological significance of the newly identified signals and those found
previously, we pursued four strategies: expression-quantitative trait loci (eQTL) analyses,
differential expression in AD versus control brains, gene cluster/pathway analyses, and
expression in AD-relevant tissues27,28. For the 24 signals reported here, other evidence indicates
that APOE29,30, ABCA731,32, BIN133, TREM212,34, SORL135,36, ADAM1037, SPI138, and CR139 are
the true AD risk gene, though there is a possibility that multiple risk genes exist in these regions40.
Because many GWAS loci are intergenic, and the closest gene to the sentinel variant may not be
the actual risk gene, in these analyses, we considered all genes within ±500kb of the sentinel
variant linkage disequilibrium (LD) regions (r2 ≥ 0.5) for each locus as a candidate AD gene 
(Supplementary Table 7).
For eQTL analyses, we identified variants in LD with sentinel variants for each locus. For
these variants, there were cis-acting eQTLs for 117 genes, with 92 eQTL-controlled genes in AD
relevant tissues (Supplementary Tables 8-11). For our newly identified loci, the most significant
eQTLs for the ADAM10 signal were for ADAM10 in blood (P = 1.21x10-13). For the IQCK signal,
the top eQTL was for DEF8 in monocytes (P = 5.75x10-48). For the ADAMTS1, signal, the most
significant eQTL was for ADAMTS1 in blood (P = 7.56x10-7). No eQTLs were found for the ACE
locus. These results indicate that ADAM10, ADAMTS1, and DEF8 were the genes responsible
for the observed association signal. For previously identified loci, there were eQTLs for BIN1 in
monocytes (P = 3.46x10-67), PVRIG in blood at the NYAP1 locus (P = 2.02x10-221), and SLC24A4
in monocytes (P = 1.27x10-34).
For our differential expression studies of AD versus control brains, we used thirteen
expression studies41. Of 469 protein coding genes within the genome-wide loci, we found 87
upregulated and 55 downregulated genes that were differentially expressed in the same direction
in two or more studies. These include four genes at the ADAM10 locus (ADAM10 and SLTM,
each upregulated in two studies; AQP9, downregulated in three studies; and LIPC, downregulated
in two studies), three genes in the IQCK locus (GPRC5B, CCP10, and GDE1 upregulated in 13,
six and four studies, respectively), six genes in the ACE locus (MAP3K3, KCNH6 and FTSJ3,
downregulated in seven, two and two studies respectively; and DDX42, PSMC5 and TANC2,
downregulated in seven, five and three studies respectively), and three genes in the ADAMTS1
locus (ADAMTS1, CYYR1, and ADAMTS5, upregulated in ten, two and two studies respectively)
(Supplementary Table 12). For previously described loci, differentially expressed genes included
TFEB near TREM2, MS4A6A (upregulated in 10 studies) at the chromosome 11 MS4A gene
cluster, and FERMT2 (upregulated in 9 studies) on chromosome 14, among others. Brain RNA-
seq data reveals many of these differentially expressed candidate genes are expressed in AD-
relevant cell types (Supplementary Table 12).
We conducted pathway analyses (MAGMA42) using five gene set resources. Analysis
were conducted separately for common (MAF > 0.01) and rare variants (MAF < 0.01). For
common variants, we detected four function clusters including: 1) APP metabolism/Aβ-formation 
(regulation of beta-amyloid formation: P = 4.56x10-7 and regulation of amyloid precursor protein
catabolic process: P = 3.54x10-6), 2) tau protein binding (P = 3.19x10-5), 3) lipid metabolism (four
pathways including protein-lipid complex assembly: P = 1.45x10-7), and 4) immune response (P
= 6.32x10-5) (Table 3 and Supplementary Table 13). Enrichment of the four pathways remains
after removal of genes in the APOE region. When APOE-region genes and genes in the vicinity
of genome-wide significant genes are removed, tau shows moderate association and lipid
metabolism and immune related pathways show strong associations (Supplementary Table 14).
Genes driving these enrichments (i.e. having a gene-wide P < 0.05) include SCNA, a Parkinson’s
risk gene that may play a role in tauopathies43,44, for the tau pathway, apolipoprotein genes
(APOM, APOA5) and ABCA1, a major regulator of cellular cholesterol, for the lipid metabolism
pathways, and 52 immune pathway genes (Supplementary Table 15). While no pathways were
significantly enriched for rare variants, lipid and Aβ-pathways did have nominal significance in 
rare-variant-only analyses. Importantly, we also observe a highly significant correlation between
common and rare pathway gene results (P = 1.32x10-7), suggesting that risk AD genes and
pathways are enriched for rare variants. In fact, 50 different genes within tau, lipid, immunity and
Aβ pathways show nominal association (P < 0.05) with LOAD (Supplementary Table 15).
To further explore the APP/Aβ-pathway enrichment we analyzed a comprehensive set of 
335 APP metabolism genes45 curated from the literature. We observed significant enrichment of
this gene-set in common variants (P = 2.27x10-4; P = 3.19x10-4 excluding APOE), with both
ADAM10 and ACE nominally significant drivers of this result (Table 4 and Supplementary Table
16 and 17). Several ‘sub-pathways’ were also significantly enriched in the common-variants
including ‘clearance and degradation of Aβ’ and ‘aggregation of Aβ’, along with its subcategory 
‘microglia’, the latter supporting the recent hypothesis that microglia play a large role in AD13,46.
Nominal enrichment for risk from rare variants was found for the pathway ‘aggregation of Aβ: 
chaperone’ and 23 of the 335 genes.
To identify candidate genes for our novel loci, we combined results from eQTL, differential
expression, AD-relevant tissue expression, and gene function/pathway analyses (Table 5). For
our ADAM10 signal, of the 17 genes within this locus, only ADAM10 meets all our prioritization
criteria. In addition, ADAM10 is the most important α-secretase in the brain and a component of 
the non-amyloidogenic pathway of APP metabolism47. Over-expression of ADAM10 in mouse
models can halt Aβ production and subsequent aggregation48. Also two rare segregating familial
LOAD ADAM10 mutations increased Aβ plaque load in “Alzheimer-like” mice, with diminished α-
secretase activity from the mutations likely the causal mechanism16,37. For the IQCK signal three
of the 12 genes at the locus are potential candidate genes: IQCK, DEF8, and GPRC5B. The latter
is a regulator of neurogenesis49,50 and inflammatory signalling in obesity51. Of the 23 genes in the
ACE locus, two meet three of the four prioritization criteria, PSMC5, a major regulator of major
histocompatibility complex52,53, and CD79B, a B lymphocyte antigen receptor sub-unit. Candidate
gene studies previously associate ACE variants with AD risk17,54,55, including a strong association
in the Wadi Ara, an Israeli Arab community with high risk of AD21. However, these studies yielded
inconsistent results18, and our work is the first to report a clear genome-wide association in NHW
at this locus. While our analyses did not prioritize ACE, it should not be rejected as a candidate
gene, as its expression in AD brain tissue is associated with Aβ load and AD severity56.
Furthermore, CSF levels of the angiotensin-converting enzyme (Ace) are associated with Aβ 
levels57 and LOAD risk58, and studies show Ace can inhibit Aβ toxicity and aggregation59 though
it does not appear to regulate cerebral amyloidosis60. Another novel genome-wide locus reported
here ADAMTS1, is within 665 kb of APP on chromosome 21. Of four genes at this locus
(ADAMTS1, ADAMTS5, CYYR1, CYYR1-AS1) , our analyses nominates ADAMTS1, as the likely
risk gene, though we cannot rule out that this signal is a regulatory element for APP. ADAMTS1
is elevated in Down’s Syndrome with neurodegeneration and AD61 and is a potential
neuroprotective gene62,63,64, or a neuroinflammatory gene important to microglial response65. For
previously reported loci, named for the closest gene, by applying the same approach for
prioritization, our analysis highlights several genes as described in Table 5. It is also interesting
to keep in mind that systematic biological screening have also highlighted some of these genes
as involved in the APP metabolism (FERMT2) or Tau toxicity (BIN1, CD2AP, FERMT2, CASS4,
EPHA1, PTK2B)66–68.
Pathway, tissue and disease traits enrichment analysis supports the utility of our
prioritization method, as the 68 prioritized genes are: 1) enriched in substantially more AD relevant
pathways and processes, 2) enriched in AD relevant tissues such as monocytes (adjusted-P=1.75
x 10-6) and macrophages (adjusted-P=6.46 x 10-3), and 3) increased in associations of dementia-
related traits (Supplementary Table 18 and 19).
Our work identifies four new genome-wide associations for LOAD, and shows that GWAS
data combined with high-quality imputation panels can reveal rare disease risk variants (i.e.
TREM2). The enrichment of rare-variants in pathways associated with AD indicates that additional
rare-variants remain to be identified, and larger samples and better imputation panels will facilitate
identifying these rare variants. While these rare-variants may not contribute substantially to the
predictive value of genetic findings, it will add to the understanding of disease mechanism and
potential drug targets. Discovery of the risk genes at genome-wide loci remains challenging, but
we demonstrate that converging evidence from existing and new analyses can prioritize risk
genes. We also show that APP metabolism is not only associated with early-onset but also late-
onset AD, suggesting that therapies developed by studying early-onset families will apply to the
more common late-onset form of the disease. Finally, our analysis showing tau is involved in late-
onset AD confirms that therapies targeting tangle formation/degradation could potentially affect
late-onset AD.
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FIGURES
Figure 1. Manhattan plot of meta-analysis of Stage 1, 2 and 3 results for genome-wide association with Alzheimer’s disease. The threshold for genome-wide
significance (P < 5 x 10-8) is indicated by the red line, while the blue line represents the suggestive threshold (P < 1 x 10-5). Loci previously identified by the
Lambert et al. 2013 IGAP GWAS are shown in green, and newly associated loci are shown in red. Diamonds represent variants with the smallest P values for each
genome-wide locus.
TABLES
Table 1. Summary of discovery stage 1, stage 2 and overall meta-analyses results for identified loci reaching genome-wide significance after stages 1 and 2.
aVariants showing the best level of association after meta-analysis of stages 1 and 2.
bBuild 37, assembly hg19.
cBased on position of top SNP in reference to the refSeq assembly
dAverage in the discovery sample.
eCalculated with respect to the minor allele.
fNot replicated in stage 2.
gPreviously the ZCWPW1 locus.
hPreviously the CELF1 locus.
Stage 1 Discovery (n=65,773) Stage 2 (n=19,884) Overall Stages 1 + Stage 2 (n=85,657)
SNPa Chr. Positionb Closest
genec
Major/
minor alleles
MAFd OR (95% CI)e Meta P
value
OR (95% CI)e Meta P value OR (95% CI)e Meta P value
Previous genome-wide significant loci still reaching significance
rs4844610 1 207802552 CR1 C/A 0.187 1.16 (1.12-1.19) 8.2 x 10-16 1.20 (1.13-1.27) 3.8 x 10-10 1.17 (1.14-1.21) 3.6 x 10-24
rs6733839 2 127892810 BIN1 C/T 0.406 1.18 (1.15-1.22) 4.0 x 10-28 1.23 (1.18-1.29) 2.0 x 10-18 1.20 (1.17-1.23) 2.5 x 10-44
rs10933431 2 233981912 INPP5D C/G 0.223 0.90 (0.87-0.94) 2.6 x 10-7 0.92 (0.87-0.97) 3.2 x 10-3 0.91 (0.88-0.94) 3.4 x 10-9
rs78738018 6 32575406 HLA-DQB1 T/A 0.270 1.10 (1.06-1.14) 5.1 x 10-8 1.11 (1.06-1.17) 5.6 x 10-5 1.10 (1.07-1.19) 1.9 x 10-11
rs75932628 6 41129252 TREM2 C/T 0.008 2.01 (1.82-2.21) 2.9 x 10-12 2.37 (1.74-3.22) 4.3 x 10-8 2.42 (1.99-2.95) 7.5 x 10-19
rs9473117 6 47431284 CD2AP A/C 0.280 1.09 (1.06-1.12) 2.3 x 10-7 1.11 (1.05-1.16) 1.0 x 10-4 1.09 (1.06-1.12) 1.6 x 10-10
rs12539172 7 100091795 NYAP1g C/T 0.331 0.93 (0.91-0.96) 2.1 x 10-5 0.89 (0.84-0.93) 2.1 x 10-6 0.92 (0.90-0.95) 9.3 x 10-10
rs11762262 7 143107876 EPHA1 T/C 0.197 0.90 (0.87-0.94) 2.1 x 10-8 0.91 (0.86-0.96) 9.6 x 10-4 0.90 (0.88-0.93) 8.2 x 10-11
rs73223431 8 27219987 PTK2B C/T 0.367 1.10 (1.07-1.13) 8.3 x 10-10 1.11 (1.06-1.16) 1.5 x 10-5 1.10 (1.07-1.13) 6.3 x 10-14
rs9331896 8 27467686 CLU T/C 0.387 0.88 (0.85-0.91) 3.6 x 10-16 0.87 (0.83-0.91) 1.7 x 10-9 0.88 (0.85-0.90) 4.6 x 10-24
rs3740688 11 47380340 SPI1h T/G 0.448 0.91 (0.89-0.94) 9.7 x 10-11 0.93 (0.88-0.97) 1.2 x 10-3 0.92 (0.89-0.94) 5.4 x 10-13
rs7933202 11 59936926 MS4A2 A/C 0.391 0.89 (0.86-0.92) 2.1 x 10-15 0.90 (0.86-0.95) 1.6 x 10-5 0.89 (0.87-0.92) 1.9 x 10-19
rs3851179 11 85868640 PICALM G/A 0.356 0.89 (0.86-0.91) 5.6 x 10-16 0.85 (0.81-0.89) 6.1 x 10-11 0.88 (0.86-0.90) 6.0 x 10-25
rs11218343 11 121435587 SORL1 T/C 0.040 0.81 (0.76-0.88) 2.6 x 10-8 0.77 (0.68-0.87) 1.2 x 10-5 0.80 (0.75-0.85) 2.8 x 10-12
rs17125924 14 53391680 FERMT2 T/C 0.093 1.13 (1.08-1.19) 6.6 x 10-7 1.15 (1.06-1.25) 5.0 x 10-4 1.14 (1.09-1.18) 1.4 x 10-9
rs12881735 14 92932828 SLC24A4 T/C 0.221 0.92 (0.88-0.95) 4.9 x 10-7 0.92 (0.87-0.97) 4.2 x 10-3 0.92 (0.89-0.94) 7.3 x 10-9
rs3752246 19 1056492 ABCA7 C/G 0.185 1.13 (1.09-1.18) 6.6 x 10-10 1.18 (1.11-1.25) 4.7 x 10-8 1.15 (1.11-1.18) 3.1 x 10-16
rs429358 19 45411941 APOE T/C 0.215 0.30 (0.28-0.31) 1.2 x 10-881 APOE region not carried forward to replication stage
rs6024870 20 54997568 CASS4 G/A 0.087 0.88 (0.83-0.93) 1.1 x 10-6 0.90 (0.83-0.97) 9.0 x 10-3 0.88 (0.85-0.92) 3.4 x 10-8
New genome-wide significant loci reaching significance
rs138190086 7 61538148 ACE G/A 0.02 1.29 (1.15-1.44) 7.4 x 10-6 1.41 (1.18-1.69) 1.8 x 10-4 1.32 (1.20-1.45) 7.5 x 10-9
rs7920721 10 11720308 ECDH3 A/G 0.389 1.08 (1.05-1.11) 1.9 x 10-7 1.07 (1.02-1.12) 3.2 x 10-3 1.08 (1.05-1.11) 2.3 x 10-9
Previous genome-wide significant loci not reaching significance
rs190982f 5 88223420 MEF2C A/G 0.390 0.95 (0.92-0.97) 2.8 x 10-4 0.93 (0.89-0.98) 2.7 x 10-3 0.94 (0.92-0.97) 2.8 x 10-6
rs4723711f 7 37844263 NME8 A/T 0.356 0.95 (0.92-0.98) 2.7 x 10-4 0.91 (0.87-0.95) 9.5 x 10-5 0.94 (0.92-0.96) 2.8 x 10-7
Table 2. Summary of discovery Stage 1, Stage 2, Stage 3 (A and B), and overall meta-analyses results for potential novel loci
reaching P <5.10-7.
Stage 1 Discovery (n=65,773) Stage 2 (n=19,884) Stage 3A (n=7,026) Overall (n=91,683)
SNPa Chr. Positionb Closestgenec
Major/Minor
allele MAF
d OR (95% CI)e Meta P OR (95% CI)e Meta P OR (95% CI)e Meta P OR (95% CI)e Meta P
rs7920721f 10 11720308 ECHDC3 A/G 0.389 1.08 (1.05-1.11) 1.9 x 10-7 1.07 (1.02-1.12) 3.2 x 10-3 1.13 (1.06-1.22) 5.9 x 10-4 1.08 (1.06-1.11) 1.2 x 10-11
rs593742 15 59045774 ADAM10 A/G 0.295 0.94 (0.91-0.97) 3.0 x 10-5 0.92 (0.87-0.97) 8.8 x 10-4 0.91 (0.84-0.99) 2.5 x 10-2 0.93 (0.91-0.95) 1.1 x 10-8
rs7185636 16 19808163 IQCK T/C 0.18 0.92 (0.89-0.96) 2.5 x 10-5 0.90 (0.85-0.95) 7.6 x 10-4 0.93 (0.85-1.01) 9.6 x 10-2 0.92 (0.89-0.95) 2.0 x 10-8
rs138190086 17 61538148 ACE G/A 0.02 1.29 (1.15-1.44) 7.4 x 10-6 1.41 (1.18-1.69) 1.8 x 10-4 1.18 (0.90-1.55) 2.4 x 10-1 1.31 (1.19-1.43) 5.0 x 10-9
rs2830500 21 28156856 ADAMTS1 C/A 0.308 0.92 (0.89-0.95) 2.5 x 10-7 0.95 (0.91-1.00) 5.7 x 10-2 0.95 (0.88-1.02) 1.7 x 10-1 0.93 (0.91-0.96) 3.2 x 10-8
rs190982 5 88223420 MEF2C A/G 0.390 0.95 (0.92-0.97) 2.8 x 10-4 0.93 (0.89-0.98) 2.7 x 10-3 0.92 (0.86-0.99) 2.4 x 10-2 0.94 (0.92-0.96) 2.4x10-7
rs4723711 7 37844263 NME8 A/T 0.356 0.95 (0.92-0.98) 2.7 x 10-4 0.91 (0.87-0.95) 9.5 x 10-5 0.96 (0.90-1.03) 3.0 x 10-1 0.94 (0.92-0.96) 2.0 x 10-7
Stage 1 Discovery (n=65,773) Stage 3B (n=26,910) Overall (n=91,683)
SNPa Chr. Positionb Closestgenec
Major/Minor
allele MAF
d OR (95% CI)e Meta P OR (95% CI)e Meta P OR (95% CI)e Meta P
- -
rs71618613 5 29005878 5p13.3 A/C 0.01 0.68 (0.57-0.80) 9.8 x 10-6 - - 0.76 (0.63-0.93) 6.8 x 10-3 0.71 (0.63-0.81) 3.3 x 10-7
aSNPs showing the best level of association after meta-analysis of stages 1, 2 and 3.
bBuild 37, assembly hg19.
cBased on position of top SNP in reference to the refSeq assembly
dAverage in the discovery sample.
eCalculated with respect to the minor allele.
fRecently identified as a LOAD locus in two separate 2017 studies
Table 3. Significant pathways (q-value≤0.05) from MAGMA pathway analysis for common SNV and rare SNV subsets.
Pathway
N genes in
pathway in
dataset
Common
SNVs P*
Common SNVs
q-value
Rare SNVs
P*
Rare SNVs
q-value Pathway description
GO:65005 20 1.45E-07* 9.53E-04 6.76E-02 8.42E-01 protein-lipid complex assembly
GO:1902003 10 4.56E-07* 1.49E-03 4.94E-02 8.42E-01 regulation of beta-amyloid formation
GO:32994 39 1.16E-06* 2.54E-03 1.78E-02 8.17E-01 protein-lipid complex
GO:1902991 12 3.54E-06* 5.80E-03 5.66E-02 8.42E-01 regulation of amyloid precursor protein catabolic process
GO:43691 17 5.55E-06* 6.75E-03 3.08E-02 8.17E-01 reverse cholesterol transport
GO:71825 35 6.18E-06* 6.75E-03 1.27E-01 8.42E-01 protein-lipid complex subunit organization
GO:34377 18 1.64E-05* 1.53E-02 1.82E-01 8.42E-01 plasma lipoprotein particle assembly
GO:48156 10 3.19E-05* 2.61E-02 7.77E-01 8.54E-01 tau protein binding
GO:2253 382 6.32E-05* 4.60E-02 2.09E-01 8.42E-01 activation of immune response
*Significant after FDR-correction (q-value≤0.05) 
Table 4. Top results of pathway analysis of Aβ-beta centered biological network from Campion et al (see Supplementary Table 12 for full results). 
Category Subcategory N Genes Common SNVs P0kb
Common SNVs P 35kb-
10kb
Rare SNVs P
0kb
Rare SNVs P
35kb-10kb
Aβ -centered biological network (all genes) -- 331 2.27E-04* 1.54E-04* 8.26E-01 5.19E-01
Clearance and degradation of Aβ -- 74 2.18E-04* 3.27E-03 3.13E-01 5.11E-01
Clearance and degradation of Aβ Microglia 47 2.24E-04* 1.83E-02 2.49E-01 6.87E-01
Aggregation of Aβ -- 35 7.09E-04* 9.93E-03 9.02E-02 1.68E-01
Aggregation of Aβ Miscellaneous 21 1.08E-03* 3.38E-02 9.53E-02 1.90E-01
APP processing and trafficking Clathrin/caveolin-dependent endocytosis 10 1.19E-03 1.15E-02 3.64E-01 1.84E-01
Mediator of Aβ toxicity -- 51 3.82E-02 4.69E-02 5.89E-01 5.70E-01
Mediator of Aβ toxicity Calcium homeostasis 6 6.90E-02 1.21E-01 3.96E-01 2.54E-01
Mediator of Aβ toxicity Miscellaneous 3 7.61E-02 2.35E-02 9.79E-01 7.61E-01
Clearance and degradation of Aβ Enzymatic degradation of Aβ 15 7.77E-02 2.63E-02 6.10E-01 2.95E-01 
Mediator of Aβ toxicity Tau toxicity 20 9.03E-02 3.48E-01 7.17E-01 6.85E-01
Aggregation of Aβ Chaperone 9 1.52E-01 3.09E-01 1.98E-01 1.13E-02
*Significant after Bonferroni correction for 33 pathway sets tested
Table 5. Top prioritized genes in significant loci based on biological evidence. Genes meeting at
least 3 of 4 criteria in each locus are listed. The criteria include: 1) differential expression in at least
one Alzheimer disease (AD) study, 2) expression in a tissue relevant to AD (astrocytes, neurons,
microglia/macrophages, oligodendrocytes), 3) having an eQTL effect on the gene in any tissue, or
having an eQTL on the gene in AD relevant tissue, and 4) being involved in a biological pathway
enriched in AD (from the current study). Novel genome-wide loci from the current study are listed
first, followed by known genome-wide loci.
Novel genome-wide loci
Locus Number ofgenes in locus Gene
Differential
expression in AD
Expression in AD
relevant tissue
eQTL in
any tissue
eQTL in AD
relevant tissue
In enriched
pathway
ADAM10 17 ADAM10
IQCK 12
GPRC5B
IQCK
DEF8
ACE 23
PSMC5
CD79B
ADAMTS1 4 ADAMTS1
Known genome-wide loci
Locus Number ofgenes in locus Gene
Differential
expression in AD
Expression in AD
relevant tissue
eQTL in
any tissue
eQTL in AD
relevant tissue
In enriched
pathway
CR1 13
CD55
CR1
BIN1 10 BIN1
INPP5D 14 INPP5D
HLA-DQB1 59
HLA-DPA1
HLA-DRA
C4A
TNXB
PSMB9
HLA-DRB6
HLA-DRB1
HLA-DRB5
HLA-DQB1
AGPAT1
AGER
HLA-DQA1
C2
BRD2
HLA-DQB2
MICB
TREM2 26 TREM2
CD2AP 8 CD2AP
NYAP1 60
GAL3ST4
EPHB4
PILRB
NYAP1
AGFG2
PILRA
GATS
EPHA1 27 No gene meets 3 of the 4 criteria; 4 genes meet 2 of the 4 criteria
PTK2B 12
PTK2B
CLU
SCARA3
CLU 16 CLU
ECHDC3 10 No gene meets 3 of the 4 criteria; 6 genes meet 2 of the 4 criteria
SPI1 25
PSMC3
MTCH2
MADD
NUP160
PTPMT1
CELF1
RAPSN
NR1H3
MS4A6A 24
MS4A6A
MS4A4A
OSBP
PICALM 12 SYTL2
PICALM
SORL1 4 SORL1
FERMT2 10
FERMT2
PSMC6
STYX
SLC24A4 11
LGMN
RIN3
SLC24A4
ABCA7 49
POLR2E
STK11
CNN2
HMHA1
CFD
ABCA7
BSG
CASS4 12 CSTF1
